chartexchange

INAB
IN8bio, Inc. Common Stock
stockNASDAQ

At CloseNov 16, 2026 3:59:37 PM EST
0.82USD-0.012%(-0.00)5,090,196
Pre-marketNov 17, 2026 9:16:30 AM EST
0.7699USD-5.650%(-0.0461)
After-hoursNov 16, 2026 4:59:30 PM EST
0.7718USD-5.867%(-0.0481)
0.6600Bid1.0500Ask0.3900Spread
Loading…
Loading…
Healthcare
Biotechnology
HQ
New York, NY, USA
Previous Close
$0.82
Beta
1.38
52-Week High
$2.73 2026-01-16
52-Week Low
$0.72 2026-11-16
SMA 50
$1.10
SMA 200
$1.38
Avg. Vol 10D
540,086
Avg. Vol 30D
203,338
Avg. Vol 90D
107,070
Relative Vol
25.03
8.13M
3.1100%
607
Jun 6, 2025 · 1-for-30 (reverse)
INAB Profile

in8bio, inc. ("in8bio") is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.

INAB Performance
PeriodPriceDateChangeBeta
1W0.902026-11-10-7.28%-0.813
1M1.112026-10-16-24.82%1.680
3M1.112026-08-17-24.82%1.417
6M1.422026-05-18-41.23%1.171
1Y1.592025-11-17-47.52%1.382
2Y9.952024-11-18-91.61%—
5Y241.502021-11-17-99.65%0.494
INAB Stock Summary

IN8bio, Inc. Common Stock (NASDAQ:INAB) stock price today is $0.83, and today's volume is 5,090,196. INAB is up 1.768% today. The 30 day average volume is 203,338. INAB market cap is $9.02M with 10.81M shares outstanding.